Abstract
3-(4-Geranyloxy-3-methoxyphenyl)-2-trans propenoic acid is a secondary metabolite biosynthetically related to ferulic acid in which a geranyl chain is attached to the phenolic group, extracted from Acronychia baueri Schott (Fam. Rutaceae). In the last five years some of the pharmacological properties of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid and its semisynthetic derivatives began to be characterized. In particular the ethyl ester showed a series of interesting biological effects such colon and tongue cancers chemoprevention by dietary feeding in rats and other effects closely related to cancer growth and development. Then 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid becomes a novel candidate as chemopreventive drug for the cure of various types of cancer and synthesis of some novel derivatives of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid, other than esters, has been recently reported. The aim of this review is to examine in detail the properties of the title compound so far reported in the literature from a chemical and pharmacological point of view.
Keywords: Acronychia baueri, Anticancer activity, Ferulic acid derivatives, 3-(4'-Geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid, Rutaceae
Anti-Cancer Agents in Medicinal Chemistry
Title: 3-(4-Geranyloxy-3-Methoxyphenyl)-2-trans Propenoic Acid: A Novel Promising Cancer Chemopreventive Agent
Volume: 6 Issue: 6
Author(s): Massimo Curini, Francesco Epifano, Salvatore Genovese, Maria Carla Marcotullio and Luigi Menghini
Affiliation:
Keywords: Acronychia baueri, Anticancer activity, Ferulic acid derivatives, 3-(4'-Geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid, Rutaceae
Abstract: 3-(4-Geranyloxy-3-methoxyphenyl)-2-trans propenoic acid is a secondary metabolite biosynthetically related to ferulic acid in which a geranyl chain is attached to the phenolic group, extracted from Acronychia baueri Schott (Fam. Rutaceae). In the last five years some of the pharmacological properties of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid and its semisynthetic derivatives began to be characterized. In particular the ethyl ester showed a series of interesting biological effects such colon and tongue cancers chemoprevention by dietary feeding in rats and other effects closely related to cancer growth and development. Then 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid becomes a novel candidate as chemopreventive drug for the cure of various types of cancer and synthesis of some novel derivatives of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid, other than esters, has been recently reported. The aim of this review is to examine in detail the properties of the title compound so far reported in the literature from a chemical and pharmacological point of view.
Export Options
About this article
Cite this article as:
Curini Massimo, Epifano Francesco, Genovese Salvatore, Carla Marcotullio Maria and Menghini Luigi, 3-(4-Geranyloxy-3-Methoxyphenyl)-2-trans Propenoic Acid: A Novel Promising Cancer Chemopreventive Agent, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/187152006778699149
DOI https://dx.doi.org/10.2174/187152006778699149 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Caspases and ROS - Dependent Mechanism of Action Mediated by Combination of WP 631 and Epothilone B
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Keratin-Based Biomaterials for Biomedical Applications
Current Drug Targets Integrins as Therapeutic Targets for Respiratory Diseases
Current Molecular Medicine Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Current Drug Targets A Review of Fertility Preservation with Radical Vaginal Trachelectomy and Laparoscopic Pelvic Lymphadenectomy in the Treatment of Early Cervical Cancer
Current Women`s Health Reviews Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer
Current Drug Discovery Technologies Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells
Current Cancer Drug Targets Anti-cancer Therapies in High Grade Gliomas
Current Proteomics Viral Origins of Human Cancer
Current Medicinal Chemistry Nasal Polyposis: From Pathogenesis to Treatment, An Update
Inflammation & Allergy - Drug Targets (Discontinued) A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Proteomics and Epigenetic Mechanisms in Stem Cells
Current Proteomics Monitoring of Treatment-Induced Apoptosis in Oncology with PET and SPECT
Current Pharmaceutical Design Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Stereoselective Synthesis and Antiproliferative Activity of Monoterpene-Fused 2- Imino-1,3-oxazines
Current Organic Synthesis